Immune Response Biopharma, Inc. (c) 2010-2025

 

Press Releases TM

Immune Response BioPharma, Inc. Announces Enters Generic Drug Market First ANDA Generic Daraprim (pyrimethamine) FDA expedited Monograph

March 30th 2021

Immune Response Biopharma Announces #NeuroVax MS Vaccine Dosing Change to Weekly Dosing to Boost Efficacy EDSS scores Pediatric remains Monthly Dosing

March 30th 2021

Immune Response Biopharma Announces #Remune Dosing Change to Monthly Dosing, to Initiate Phase 1 Preventive HIV Phase I Work, Pediatric verified safe effective remains Quarterly Dosing

March30th 2021

 

Immune Response BioPharma, Inc. Update 2021-2022 Guidance Revenues $5-250M will vary upon partnering, ICO Tokenization, IRBP Tier One Capital balance sheet target of 15%, File new patents, Phase I RespiResponse Covid Vaccine begin manufacturing, Update FDA IND Fast Track Request,  Seek EMA emergency use authorization for antibody cocktail universal covid white blood cell TCR peptide vaccine RespiResponse

Feb 20th 2021

Immune Response BioPharma, Inc. Update to Launch ICO in Switzerland to fund Blockbuster Universal Coronavirus Vaccine RespiResponse IR101C Development on Track IND completion a DNA white blood cell vaccine robust T Cell antibody cell mediation with weekly dosing safe effective V Beta 13.1 in IFA adjuvant & .09%sodium chloride the main NeuroVax FDA Fast track MS vaccine powers RespiResponse used in a half dozen human trials previously all patients induced T cell immunity this is the most potent and powerful vaccine ever developed with over 1000 times binding affinity than remdesiver. IRBP has updated the FDA on timelines for RespiResponse IND filing and development.

August 28th 2020

 

Immune Response BioPharma, Inc. addressing technical BLA Remune pediatric BLA filing eCTD requirements will refile under protest with the FDA by 2022.

August 28th 2020

 

Immune Response BioPharma Inc.,New Hepatitis Vaccine IR101H LivaVax formulation is complete. A Novel triple TCR peptide white blood cell Vaccine, a first in class and best in class  universal Hepatitis Vaccine for all three viruses Hep A Hep B and Hep C. IRBP believes the TCR peptide vaccine can down regulate and up regulation of the immune system for cell mediation of the various Hepatitis virus strains. Dosing is monthly, IRBP to file new IND and seek Breakthrough FDA designation.

April 13th 2020 

 

Immune Response BioPharma,Inc., To Seek FDA emergency use of RespiResponse  IR101C Treatment dose V Beta peptides similar to NeuroVax  for cell mediated responses a white blood cell vaccine.; IRBP enters dialogue with FDA on Expedited Approval. IRBP expects RespiResponse to be 100% effective with 95% Gene Sequencing of Lung & coronavirus Gene types with 95% confidence interval.

March 19th 2020

 

Immune Response BioPharma, Inc. Announces New Whole Killed SARS/Coronavirus Vaccine IR101C Formulation is Complete a new IND will be filed with the FDA and commence work on RespiResponse IR101C. RespiResponse a novel first in class two dose vaccine consists of Depleted GP S spike, Devoid of outter envelope and proteiens chemical killed in beta propiolactone and Gamma Irradiationin in HUT78 cell line in IFA adjuvant, Second Dose a novel Peptide VB V Beta sequenced gene type 100% in IFA adjuvant for cell mediated immune responses and neutralizing enzymes.white blood cell vaccine. IRBP demonstrates our vaccine platform is superior and the global leader in vaccine technology. IRBP will seek Breakthrough desigation with the FDA for RespiResponse a universal Coronavirus vaccine.

January 28th 2020

Immune Response BioPharma Inc. New Whole Killed Ebola Vaccine IR101E Formulation is Complete a New IND submission will be filed with the FDA. EmuneVax consists of Depleted VP24 & VP 40 and outer envelope GP1   &GP2 chemical killed in beta propiolactone & Gamma Irradiation in HUT78 cell line in IFA adjuvant. This is a first in class & best in class vaccine utilizing the original strain from Zaire.  Immune Response  vaccine technology is superior & demonstrates IRBP is the leader in infectious diseases. IRBP will begin planning for Phase I work and manufacturing. The HUT78 cell line has a cell.mediated antibodies against Ebola virus and is difficult to infect & induces cell mediated response s. We believe our Ebola vaccine will become vaccine of choice.

December 30th 2019

 

Immune Response BioPharma Inc. Update on Remune BLA for Adults Remune Delayed as per the FDA "HIV Patients would stop taking their HIV antiviral drugs" if Remune is Approved widely available: IRBP is Exploring all legal avenues to address the CRL including arbitration .IRBP finds the govt's position to be wholly unacceptabe keeping Remune off the market.

 

 

 

 

 

 

 

 

                        Immune Response BioPharma, Inc.TM Copyright (C) 2010-2025  All Rights Reserved 

                                                                www.immuneresponse.net